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Abstract The anti-p21ras Y13-259 single-chain Fv fragment
(scFv) neutralizes the activity of p21-ras when intracellularly
expressed in different systems. We have studied the mode of
action of this inhibition in 3T3 K-ras fibroblasts and demon-
strated that (i) this antibody fragment is highly aggregating when
cytoplasmically expressed and (ii) the p21-ras antigen is
sequestered in these aggregates in an antibody-dependent
manner. This co-segregation leads to an efficient inhibition of
DNA synthesis. These results suggest that an antigen can be
diverted from its normal location inside the cells in an antibody
mediated way, prospecting a new mode of action for intracellular
antibodies in vivo.
z 1998 Federation of European Biochemical Societies.
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1. Introduction
The intracellular antibody technology is based on the idea
that antibody chains or domains, if equipped with suitable
targeting signals, could be targeted towards new ectopic intra-
cellular sites to neutralize selected gene products [1,2]. This
approach has been successfully applied to inhibit the function
of several intracellular antigens in the cytoplasm, nucleus and
in the secretory pathway of di¡erent biological systems [2,3].
One of the problems encountered from the very initial
phases of the intracellular antibody work was related to the
limited half life of antibodies and of antibody domains ex-
pressed in the cell cytoplasm. The reducing environment of
the cell cytoplasm hinders the formation of the intrachain
disul¢de bonds of the VH and VK domains, which are im-
portant for the stability of the folded protein. Indeed, the
intrachain disul¢de bond does not form in scFv fragments
expressed in the cytoplasm of eukaryotic cells [4]. The use
of vectors optimized for the subcellular targeting of scFv anti-
body fragments in mammalian cells led to higher expression
levels, although this did not always result in higher levels of
soluble protein [5]. In this respect, di¡erent scFv fragments
have distinct properties when expressed in the cytoplasm of
mammalian cells, in terms of solubility and propensity to
aggregate [6]. While some show a di¡use intracellular distri-
bution, typical of soluble cytoplasmic proteins, others form
intracellular aggregates and are concentrated in granular
structures, whose number and size vary for each scFv, being
typical for each antibody. It is not clear if the aggregating
intracellular antibodies are able to interact with the antigen,
and, in doing so, they are able to neutralize its function. In
view of this fact, there is a great interest in selecting or en-
gineering ‘superframeworks’ putatively more suitable for in-
tracellular expression [6^8].
The anti-p21ras Y13-259 scFv fragment has been shown to
inhibit the insulin induced meiotic maturation in Xenopus oo-
cytes [9,10], in a well controlled experimental situation. In this
model system both the whole antibody molecules and the scFv
fragments are e⁄ciently expressed in the cytoplasm in a solu-
ble form, co-localize with the antigen p21ras in the submem-
branous compartment, and inhibit its function by neutraliza-
tion of the epitope (amino acids 60^76) within the switch II
region of p21 ras. In this simplest mode of action, soluble
intracellular antibodies act as competitive binders, in a stoi-
chiometric ratio with respect to the antigen.
Evidence for the neutralization of p21ras activity in mam-
malian cells by the intracellular expression of Y13-259 scFvs
has also been presented [11,12]. Moreover, as a step towards
cancer gene therapy, intratumor transduction of HCT116 co-
lon carcinoma cells with the Y13-259 scFv using an adenovi-
ral vector leads to tumor regression in nude mice [13]. In these
studies, neither data on the intracellular interaction between
p21ras and the scFv, nor on the solubility state of the intra-
cellular scFv were reported.
In this paper we have expressed the scFv fragment Y13-259
in mouse 3T3 K-ras transformed ¢broblasts. We demon-
strated that this antibody fragment is highly aggregating in
the cytoplasm of mammalian cells, and that, nothwithstanding
this fact, the p21-ras antigen is sequestered in these aggregates
into an insoluble form. As a consequence, bromodeoxyuridine
incorporation assays show that cell proliferation is highly in-
hibited in Y13-259 transfected cells. These results suggest that
the antigen can be segregated from its normal location inside
the cells, in an antibody mediated way, prospecting a new
mode of action for intracellular antibodies in vivo.
2. Materials and methods
2.1. Plasmids
For the expression of antibody fragments in mammalian cells, plas-
mids pscFvexp-cyt-Y13-259 and pscFvexp-cyt-K-D11 were con-
structed by subcloning the NcoI-NotI fragments from pcDNA-
neoY13-259cyt [14,4] and pcDNAneo-K-D11sec [15,4] into the
pscFvexpress-cyt vectors [5]. The pscFvexp-cyt-C12 was kindly pro-
vided by Ljdia Persic, and directs the expression of the anti-p21-ras
scFv fragment C12, isolated from an antibody phage library (Persic et
al., manuscript in preparation). All vectors direct the expression of
cytosolic antibody fragments under the transcriptional control of the
EF-BOS (elongation factor-1a) promoter.
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2.2. Cell lines, transfection and Western blot analysis
COS simian and murine 3T3 K-ras ¢broblasts (kindly provided by
Claudio Schneider) were grown in DMEM medium supplemented
with 10% fetal calf serum.
COS cells were transiently transfected by DEAE-dextran and 3T3
K-ras were transfected by incubation with Superfect transfection re-
agent (Qiagen), following the manufacturer’s instructions, with a
DNA/superfect reagent ratio (w/v) of 1:10. Cells were harvested and
analyzed 48 h after transfection. Transfected cells were washed with
PBS, lysed for 15 min in ice cold extraction bu¡er (Tris-Cl 20 mM,
pH 8, MgCl2 20 mM, 0.5% NP40, 0.1 mg/ml leupeptin, chymostatin
and 0.1 mM PMSF) and centrifuged for 15 min (12 000 rpm). The
pellet (insoluble pool) and the supernatant fractions (soluble pool)
were analyzed by Western blot using the anti-myc mouse monoclonal
antibody 9E10 and the human recombinant anti-ras Y13-259 [16] as
primary antibodies and goat anti-mouse or goat anti-human horse-
radish peroxidase (Sigma) as secondary antibody. The blots were vis-
ualized by ECL detection kit (Amersham).
2.3. Immuno£uorescence
Cells were grown on glass coverslips coated with poly-L-lysine, then
rinsed three times in PBS and ¢xed for 10 min with 4% (w/v) para-
formaldehyde (in PBS). Cells were permeabilized for 5 min with 0.2%
Triton X-100 in 100 mM Tris-HCl (pH 7.5). Incubation with a⁄nity
puri¢ed mouse anti-myc 9E10 and human recombinant anti-ras Y13-
259 was carried out at room temperature for 1 h; £uorescein-isothio-
cyanate-conjugated goat anti-mouse IgG and goat anti-human bioti-
nylated followed by Texas Red streptavidin were used for detection.
Samples were routinely examined with a Leitz Dialux 22 micro-
scope, equipped with a 50U water-immersion objective. Confocal
analysis was carried out with a Leica TCS 4D system, equipped
with a 100U 1.3^O.6 oil immersion objective.
2.4. Bromodeoxyuridine (BudR) incorporation
Transfected 3T3 K-ras cells, after incubation with BudR 10 WM for
24 h, were ¢xed and permeabilized with 70% ethanol in 50 mM gly-
cine bu¡er, pH 2, for 30 min at 320‡C. BudR incorporation into
DNA was detected by immuno£uorescence by incubating the cells
with mouse monoclonal antibody against BudR (Boehringer-Mann-
heim) containing nucleases for DNA denaturation, followed by anti-
mouse biotinylated antibody (Amersham) and streptavidin-Texas Red
(Amersham). BudR positive cells were counted from non-transfected
cultures and from pscFvexp-cyt-Y13-259 and pscFvexp-cyt-K-D11
transfected cells. The results shown in Fig. 4 are the average from
three di¡erent experiments. At least 50^70 positively transfected cells
were counted for each transfected cell population in each experiment.
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Fig. 1. A: COS cells transfected with Y13-259 (a), K-D11 (b) and C12 (c) scFv fragments targeted to the cytoplasm, viewed by immuno£uores-
cence with anti-myc tag antibodies (monoclonal antibody 9E10) and confocal analysis. B: Western blot analysis of the transfected cell popula-
tions shown in A, with anti-myc tag antibodies (monoclonal antibody 9E10). Soluble and insoluble proteins were extracted as described in Sec-
tion 2. Arrow points to the scFv fragment band.
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3. Results
Di¡erent scFv fragments show distinct propensity to aggre-
gate when expressed in the cytoplasm of mammalian cells.
While some show, in immuno£uorescence studies, a di¡use
intracellular staining typical of soluble cytoplasmic proteins,
others are concentrated in granular structures, whose number
and size vary for each scFv [6].
3.1. Co-localization of cytoplasmic Y13-259 and p21ras in
intracellular aggregates
In Fig. 1 we have compared the intracellular distribution of
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Fig. 2. Double immuno£uorescence with anti-p21ras antibody (A,D) and anti-myc (B,E) demonstrating the co-localization of cytoplasmic scFv
fragment and p21ras protein only in cells expressing the scFv Y13-259 (F,G), but not in cells expressing the scFv K-D11 (C). A, B and C: 3T3
K-ras ¢broblasts transfected with pscFvexp-cyt-K-D11. D, E, F and G: 3T3 K-ras ¢broblasts transfected with pscFvexp-cyt-Y13-259. F and G
represent two images of a series of the same ¢eld.
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the anti-p21ras scFv fragment Y13-259 with that of the anti-
NGF scFv K-D11, when expressed in COS cells as cytoplas-
mic proteins. Both scFv fragments concentrate in intracellular
granules (Fig. 1A, a and b), a property which is diagnostic of
a high insolubility, as con¢rmed by Western analysis of the
soluble and insoluble pool of the two antibody fragments
(Fig. 1B, a and b). Under the same cellular conditions, other
scFv fragments, cloned in identical vectors harboring the same
promoter, show a more di¡use distribution (Fig. 1A, c) and
are recovered (mostly) in the soluble pool (Fig. 1B, c), under
comparable overall expression levels.
In order to verify whether the intracellularly aggregated
Y13-259 scFv fragments are able to interact with the p21ras
in the cytoplasm, transformed 3T3 ¢broblasts, expressing high
levels of Ki-ras, have been transfected with the antibody frag-
ments Y13-259 (anti-p21ras) and with the non-relevant con-
trol scFv K-D11. The intracellular distribution of the scFv
fragments and of the p21-ras protein was studied in the trans-
fected cells by double immuno£uorescence and analyzed by
confocal microscopy (Fig. 2A, B and C for K-D11 expression
and D, E, F and G for Y13-259 expression). Cells are viewed
with anti-p21-ras antibody (Fig. 2A and D) and with anti-myc
antibody (Fig. 2B and E). The combination of the two £uo-
rescence patterns is shown in Fig. 2C for K-D11 expression
and F and G for Y13-259 expression. In these images the
signal viewed with the anti-ras antibody (green) and the signal
viewed by anti-myc (red) were combined and the two chro-
mophores are superimposed in the same image with a green/
red color scale, leading to yellow color in case of co-local-
ization. As can be seen, in K-D11 transfected cells anti-ras
(green) and anti-myc (red) does not co-localize, whereas in
Y13-259 transfected cells the two signals appear condensed
in the same yellow aggregates.
3.2. Segregation of p21ras into an insoluble form
From the co-localization experiments, it appears that the
protein p21ras is speci¢cally segregated in granules in those
cells which are positive for the Y13-259 scFv fragments.
To verify whether the scFv fragments and p21ras protein
co-localize in an aggregated and insoluble form, the soluble
and insoluble fractions were analyzed by Western blot (Fig. 3)
of a population of 3T3 K-ras ¢broblasts, comprising around
5% of cells transiently transfected with Y13-259 or K-D11.
This experiment shows that: (i) both Y13-259 and K-D11
are found in the insoluble pool (Fig. 3, right, lanes 1 and 2)
and totally absent in the soluble pool (Fig. 3, left, 1 and 2);
(ii) p21ras is a soluble protein and can be detected with anti-
ras antibodies among the soluble proteins of both 3T3 cell
populations; (iii) interestingly, in extracts derived from 3T3
cells transfected with Y13-259, a consistent fraction of p21ras
can be visualized with anti-ras antibodies in the unsoluble
pool (Fig. 3, right, lane 3). Pulse and chase experiments
with metabolic labeling of cells, followed by immunoprecipi-
tation, con¢rmed that even the neosynthesized Y13-259 pro-
tein cannot be recovered as a soluble protein (data not
shown).
This further suggests that the intracellular Y13-259 anti-ras
antibodies are interacting in vivo with the p21-ras antigen,
diverting it from its normal location and changing its solubil-
ity state.
3.3. Y13-259 scFv intracellular fragments block DNA synthesis
p21ras proteins can only exert their stimulation of cellular
proliferation when associated to the plasma membrane. Di-
verting p21ras from its location would result in the inhibition
of its function.
To verify whether the expression of the anti-ras scFv Y13-
259 would inhibit the signaling for the induction of DNA
synthesis, the incorporation of bromodeoxyuridine was deter-
mined in 3T3 K-ras cells, transfected with pscFvexp-cyt-Y13-
259 and pscFvexp-cyt-K-D11. Fig. 4 shows that the expression
of the anti-ras intracellular scFv fragments resulted in a great
inhibition of DNA synthesis, with less than 10% of cells enter-
ing DNA synthesis, compared to 70^75% of cells non-trans-
fected, or transfected with the anti-NGF antibody fragments.
This demonstrates that Y13-259 segregates p21-ras into an
insoluble and inactive form.
4. Discussion
Although for any given scFv fragment the solubility is
partly dependent on the overall expression levels [5], under
identical conditions of intracellular expression scFv fragments
can have very distinct solubility properties, regardless of the
presence of the antigen. Their performance depends primarily
on their amino acid sequence, in a way that is as yet unpre-
dictable [6].
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Fig. 3. Western blot analysis of 3T3 K-ras ¢broblasts transfected
with scFv fragment indicated below each lane and probed with anti-
bodies shown above. Left panel: Soluble pool of proteins. Right
panel: Insoluble pool of proteins. The upper arrow indicates the mi-
gration of the scFv fragments, while the lower indicates the migra-
tion of p21ras protein. Exposure times (ECL detection system) were
1 and 30 min for the left and right panel, respectively. Overexposure
of the ¢rst two lanes in the left panel up to 100-fold longer times
did not reveal the presence of soluble scFv bands.
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When expressing proteins ectopically, and scFv fragments
in particular, aggregation is often a problem. This is a natural
phenomenon that also occurs during the maturation of newly
synthesized native proteins and represents an o¡-pathway of
the normal folding process [17]. In some cases the folding
intermediate implicated in the aggregation has been shown
to have a signi¢cant native-like structure, but the generality
of this fact remains to be proven. In particular, for aggregat-
ing scFv fragments, no binding data on the intermediate fold-
ing state are available, also because of the di⁄culty in acquir-
ing this type of data. This information represents an
important issue for the mode of action of intracellular anti-
bodies.
In this paper we have shown that the Y13-259 scFv, as well
as other scFv fragments, including the K-D11 anti-NGF scFv,
is totally insoluble when expressed in the cytoplasm of mam-
malian cells. The same scFv was soluble in the cytoplasm of
Xenopus laevis oocytes [9,10], most likely due to the lower
temperature used in those experiments (18‡C vs. 37‡C). The
property of aggregation appears to be shared by di¡erent scFv
fragments, regardless of the presence of the corresponding
antigen. Yet, only cells expressing the aggregated Y13-259
scFv show a dramatic redistribution of the intracellular local-
ization of the p21ras protein, which is now found in the same
granular structures as the scFv fragment in a largely insoluble
form. It can be concluded that a speci¢c interaction between
the co-expressed Y13-259 scFv fragment has occurred, there-
by leading to their co-segregation, although the timing of this
interaction is still an open question. At steady state, the scFv
fragments are shown to be totally insoluble and aggregated,
but our results suggest that some intermediate state in the
biosynthesis of the cytoplasmic scFv fragment, before it
reaches the aggregated state, displays native-like binding
properties. This native-like state may be a putative intermedi-
ate state representing a bifurcation point in the pathways for
folding and aggregation [17]. Following this initial speci¢c
binding event, further progress towards aggregation would
recruit the p21ras antigen, sequestering it in the aggregate,
in a reaction that may be reminiscent of an intracellular im-
munoprecipitation. It is noteworthy that the aggregated
p21ras is detected also using the same Y13-259 antibody,
showing that not all the epitopes are engaged with the intra-
cellularly expressed Y13-259. This can be interpreted either by
assuming that the ‘trapped’ p21ras has a multimeric quater-
nary structure (dimeric or more), or, alternatively, that in the
cellular structures where the scFv and the p21ras are selec-
tively co-localized the complex dissociates, possibly due to an
unfavorable pH. Attempts to isolate and characterize the cel-
lular granules containing the scFv and the antigen are pres-
ently under way.
We have con¢rmed that the biological action of the p21ras
protein is e¡ectively and speci¢cally neutralized in the cells
expressing the cytoplasmic scFv, as revealed by inhibition of
bromodeoxyuridine incorporation. The intracellular antibod-
ies might act to divert the antigen from its normal location,
with a mode of action that leads to a segregation of an anti-
gen in vivo. In this case, the signal for tra⁄c diversion is
provided by an aggregating antibody. Learning how to con-
trol this process, that may represent an unwanted property of
an antibody, will broaden the spectrum of possible modes of
action for intracellular antibodies [2]; for instance, learning
how the cell disposes or deals with the granules observed
under these conditions.
In the case reported in this paper, the scFv fragment is a
neutralizing one. It is possible that the neutralization of
p21ras occurs, at least partially, prior and independently of
the aggregation events leading to the sequestration of p21ras,
by a subset of soluble scFv molecules. However, whilst this
may certainly contribute to the observed inhibition, it is un-
likely to represent the major mechanism of action, given the
vast majority of insoluble molecules. Indeed, tra⁄c diversion
only needs good and speci¢c binding properties and this mode
of action, based on antigen sequestration, eliminates the need
of expressing scFv fragments against neutralizing epitopes.
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Fig. 4. Bromodeoxyuridine incorporation. BudR positive cells were counted from non-transfected cells (n t), pscFvexp-cyt-K-D11 (K-D11) and
pscFvexp-cyt-Y13-259 (Y13-259) transfected cells. The ¢gure shows the average from three di¡erent experiments. At least 50^70 positively
transfected cells were counted in each experiment.
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Implementing selection schemes whereby cells are selected on
the basis of the phenotype conferred by the intracellular anti-
bodies may help to overcome the potential problems of the
aggregating antibodies [18].
The results also have implications for understanding the
folding process of antibody fragments under these highly ar-
ti¢cial conditions. Whilst it is certainly true that some anti-
bodies fold much better than others under intracellular ex-
pression conditions [6^8], the present results prospect the
possibility that intermediate folding states may display na-
tive-like binding properties. In this case, the intracellular ex-
pression has provided a biological read-out for detecting and
amplifying a binding event that would not be experimentally
accessible in an easy way by other means. The potential for
this experimental approach, based on intracellular antibodies,
for the study of the folding intermediates is being explored.
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